Regorafenib (Bay 73-4506) is an oral multi-kinase inhibitor that exerts its anti-tumor effect by blocking and inhibiting the activity of multiple protein kinases involved in tumor angiogenesis, tumorigenesis, metastasis, and tumor immunity [17]. The gene discussed is WEE1; the disease is neoplasm.